Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases
Disease area: Airway diseases

Abstract

Introduction:Serum periostin is a potential biomarker of response to therapies which target a T-helper 2 (Th2) pattern of inflammation in asthma.Aims:To determine serum periostin levels in a random sample of adults with symptoms of airflow obstruction, its relationship with other variables, including other biomarkers of a Th2 pattern of disease, and the change in serum periostin levels with inhaled corticosteroid (ICS) treatment.Methods:Serum periostin levels were determined as part of the New Zealand Respiratory Health Survey, a cross-sectional study designed to explore phenotypes and biomarkers in individuals aged 40 to 75 who reported wheeze and breathlessness in the last 12 months (n=386). 49 steroid naïve subjects had repeat periostin testing after 12 weeks open label ICS (budesonide 800 mcg/day).Results:Serum periostin values ranged from 15.0ng/ml to 164.7ng/ml, with a right skewed distribution. Mean (SD) periostin was 57.3 (18.6), median (IQR) 54.0 (45.1 to 65.6). Periostin was positively correlated with exhaled nitric oxide (r=0.22, p<0.001), blood eosinophils (r=0.21, p<0.001), and total IgE (r=0.14, p=0.007). Atopy was associated with a higher mean periostin level (59.4 v 53.9, p=0.002; median 55.9 v 51.0). Gastro-oesophageal reflux was associated with a lower mean periostin (54.6 v 59.6, p=0.002; median 51.5 v 55.9).Twelve weeks of ICS therapy in steroid naïve participants was associated with a 10% reduction in mean periostin, from 52.9 to 47.6, median periostin reduced from 49.8 to 47.3.Conclusion: Serum periostin is a marker of a Th2 pattern of airways disease, and a course of ICS therapy leads to a mean reduction in serum periostin levels of 10%.

Rating:

Share or cite this content

Citations should be made in the following way:
J. Fingleton, J. Travers, D. Bowles, R. Strik, R. Siebers, C. Holweg, J. Matthews, M. Weatherall, R. Beasley (Wellington, Lower Hutt, San Francisco, New Zealand). Serum periostin in obstructive airways disease: Range, relationships and response to corticosteroid. Eur Respir J 2014; 44: Suppl. 58, 3873

Member's Comments

No comment yet.

Related content which might interest you: Comparison of inflammatory markers in induced and spontaneous sputum in COPD patients Source: International Congress 2014 – Translational studies in COPD Year: 2014 Association between airway inflammation, airway remodelling and physiological changes in asthma Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 The U-BIOPRED severe asthma study: Immunopathological characterisation Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Disturbed pulmonary immunity and the phenotype of alveolar macrophages in bronchial asthma, gastroesophageal reflux disease and their combination Source: International Congress 2014 – New insights into monocyte and macrophage biology Year: 2014 Interleukin-18 levels in induced sputum of stable and exacerbated COPD patients Source: International Congress 2014 – Translational studies in COPD Year: 2014 Role of IL-33/ST2 axis in systemic inflammation of allergic airway disease Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Plasma cytokine levels in non-smoking and smoking patients with COPD Source: International Congress 2014 – Translational studies in COPD Year: 2014 Serum periostin in asthma: A potential biomarker for stratification in severe treatment-resistant asthma Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 The airway microbiota is significantly altered in subjects with eosinophilic asthma Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Osteopontin and periostin in bronchial tissue associate with a 20-year decline of pulmonary function in asthmatics Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014 Biomarkers for sputum eosinophilia in mild-moderate and severe adult-onset asthma patients Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014 Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD Source: International Congress 2014 – Translational studies in COPD Year: 2014 Multi-analyte profiling of inflammatory markers in COPD sputum Source: International Congress 2014 – Translational studies in COPD Year: 2014 The role of circulating mitochondrial DNA in modulating airway inflammation of chronic obstructive pulmonary disease Source: International Congress 2014 – Cell biology 2014 Year: 2014 Airway inflammation in patients with different levels of asthma control Source: Annual Congress 2013 –Asthma: new mechanisms and markers Year: 2013 LSC 2014 abstract - Epithelial to mesenchymal transition in the airway epithelium from COPD patients: Correlation to disease severity Source: International Congress 2014 – Mechanistic studies of the airway epithelium Year: 2014 Modulation of neutrophil functionalities by indacaterol and their relevance for chronic lung diseases Source: International Congress 2014 – Translational studies in COPD Year: 2014 Association between body mass index (BMI) and markers of eosinophilic inflammation in asthma Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Ration of IL1beta / IL1-receptor antagonist (RA) in alveolar macrophages of induced sputum of patients with asthma during long-term follow-up Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 U-BIOPRED asthma cohort: Inflammatory markers and corticosteroid use Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013